Get the Stockscreener App
513.21
0.04%
0.19
Madrigal Pharmaceuticals Inc stock is traded at $513.21, with a volume of 219.33K.
It is up +0.04% in the last 24 hours and up +0.24% over the past month.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
See More
Previous Close:
$513.02
Open:
$513.65
24h Volume:
219.33K
Relative Volume:
0.65
Market Cap:
$11.86B
Revenue:
$1.13B
Net Income/Loss:
$-309.44M
P/E Ratio:
-40.09
EPS:
-12.8001
Net Cash Flow:
$-275.41M
1W Performance:
-3.97%
1M Performance:
+0.24%
6M Performance:
+15.32%
1Y Performance:
+20.23%
1-Day Range:
$510.57
$521.77
1-Week Range:
$502.62
$537.73
52-Week Range:
$393.61
$615.00
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Name
Madrigal Pharmaceuticals Inc
Sector
Industry
Phone
404-380-9263
Address
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Compare MDGL vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
513.21 | 11.86B | 1.13B | -309.44M | -275.41M | -12.80 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Initiated | Barclays | Overweight |
| Jan-06-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Nov-05-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-03-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Oct-15-25 | Initiated | Truist | Buy |
| Sep-04-25 | Resumed | H.C. Wainwright | Buy |
| Feb-28-25 | Upgrade | B. Riley Securities | Neutral → Buy |
| Feb-27-25 | Reiterated | H.C. Wainwright | Buy |
| Jun-28-24 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Apr-22-24 | Initiated | BofA Securities | Underperform |
| Mar-15-24 | Upgrade | B. Riley Securities | Sell → Neutral |
| Mar-06-24 | Initiated | Citigroup | Buy |
| Feb-26-24 | Downgrade | B. Riley Securities | Neutral → Sell |
| Dec-20-22 | Reiterated | Oppenheimer | Outperform |
| Dec-19-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-22 | Reiterated | Piper Sandler | Overweight |
| Dec-19-22 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jul-08-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| May-20-21 | Resumed | Goldman | Buy |
| Nov-24-20 | Resumed | Evercore ISI | Outperform |
| Nov-06-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-05-20 | Initiated | BMO Capital Markets | Market Perform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-20 | Initiated | Canaccord Genuity | Buy |
| Jan-09-20 | Upgrade | UBS | Neutral → Buy |
| Nov-07-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-19 | Initiated | Stifel | Hold |
| Jun-10-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Feb-28-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
| Jan-23-19 | Initiated | UBS | Neutral |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Dec-12-18 | Initiated | B. Riley FBR | Neutral |
| Nov-19-18 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Nov-16-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Sep-04-18 | Initiated | Citigroup | Buy |
| Aug-06-18 | Downgrade | Goldman | Buy → Neutral |
| Jun-28-18 | Initiated | Raymond James | Mkt Perform |
View All
Madrigal Pharmaceuticals Inc Stock (MDGL) Latest News
MDGL Reinstated by Goldman Sachs -- Price Target Announced at $7 - GuruFocus
Goldman Sachs assumes Madrigal Pharmaceuticals stock with buy rating By Investing.com - Investing.com Canada
Goldman Sachs Reinitiates Coverage on Madrigal Pharmaceuticals (MDGL) with Buy Rating and $704 Price Target - GuruFocus
Madrigal Pharmaceuticals Inc (YDO1.DU) valuation measures and financial statistics - Yahoo Finance Australia
MDGL Initiates Coverage On Citigroup -- Price Target Announced a - GuruFocus
Citi Initiates Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Announces Target Price $725 - Moomoo
Citigroup Initiates Madrigal Pharmaceuticals at Buy With $725 Price Target - finance.yahoo.com
Madrigal Pharmaceuticals stock falls 1.80 percent as valuation stays high - AD HOC NEWS
(MDGL) Volatility Zones as Tactical Triggers - Stock Traders Daily
Madrigal Pharmaceuticals stock trades around 531 dollars as institutional interest stays strong - AD HOC NEWS
Madrigal Pharmaceuticals, Inc. (MDGL): Investor Outlook on a Biotech Powerhouse with 27.57% Potential Upside - DirectorsTalk Interviews
Madrigal Pharmaceuticals stock holds above 530 dollars after recent ownership change - AD HOC NEWS
Madrigal Pharmaceuticals stock holds near $531 after fresh analyst data - AD HOC NEWS
How New Headquarters At Madrigal Pharmaceuticals Stock Has Changed Its Investment Story - simplywall.st
Madrigal Pharmaceuticals Inc (YDO1) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Have Insiders Sold Madrigal Pharmaceuticals Shares Recently? - simplywall.st
MDGL Stock In Focus — Retail Traders Buzz Over M&A Speculation And Fresh Patents For Liver Drug - Stocktwits
Understanding Momentum Shifts in (MDGL) - Stock Traders Daily
Madrigal Pharmaceuticals (NASDAQ: MDGL) insider plans another stock sale after recent multimillion-dollar trades - Stock Titan
Madrigal Pharmaceuticals, Inc. Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Madrigal at cantor healthcare conference: growth, access and pipeline By Investing.com - Investing.com Nigeria
Madrigal Pharmaceuticals, Inc. Rings the Closing Bell - Nasdaq
Madrigal at cantor healthcare conference: growth, access and pipeline - investing.com
Institutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You? - Yahoo Finance
Madrigal Pharmaceuticals (NASDAQ: MDGL) exec plans $3.4M stock sale for tax withholding - Stock Titan
September 2026 Nasdaq Stock Market Bell Ceremonies - Nasdaq
Madrigal to Put MASH Drug Strategy Before Investors at Cantor - MyChesCo
Madrigal Pharmaceuticals (MDGL) Stock Analysis: A 25% Upside Potential In Biotech Innovation - DirectorsTalk Interviews
Madrigal Doubles Down On MASH With A $4.4 Billion Licensing Deal With China’s Ribo - Stocktwits
Madrigal Pharmaceuticals (MDGL) Leads Healthcare CapEx Growth Am - GuruFocus
Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference - The Manila Times
Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis: A 27% Upside Potential Amid Biotech Innovation - DirectorsTalk Interviews
Madrigal Pharmaceuticals (MDGL) Declines 1.83% to $533.76 as Consolidation ContinuesShort Setup Alerts - careplusvn.com
Madrigal Grants Stock Awards to 13 New Employees - MyChesCo
Here's Exactly What It Will Take for Madrigal Pharmaceuticals Stock to Take Off - finance.yahoo.com
Madrigal Pharmaceuticals, Inc. (MDGL) Stock Report: Analysts See 31% Upside Potential with Strong Buy Ratings - DirectorsTalk Interviews
When Will Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Become Profitable? - 富途牛牛
Madrigal Pharmaceuticals' General Counsel Executes Automatic Sale of 664 Shares to Cover Tax Withholding - Kalkine Media
Shannon Kelley Sells 664 Shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock - MarketBeat
Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule - TradingView
Madrigal (NASDAQ: MDGL) GC has 664 shares sold for RSU taxes - Stock Titan
Madrigal Pharmaceuticals (MDGL) Stock May Look Cheap On Sales But Risky On Cash Flow - simplywall.st
Exploring 3 High Growth Tech Stocks In The US Market - Sahm
Madrigal Adds J&J R&D Chief to Board as MASH Push Expands - MyChesCo
Madrigal (NASDAQ: MDGL) awards Reed 647 RSUs and options on 1,078 shares - Stock Titan
Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis: A Biotech Powerhouse with 33.59% Upside Potential - DirectorsTalk Interviews
Madrigal (NASDAQ: MDGL) officer plans $337K sell-to-cover trade - Stock Titan
2,410 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Acquired by State of Wyoming - MarketBeat
Madrigal’s Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands - MarketBeat
Madrigal Uses Equity Awards to Recruit 10 Employees - MyChesCo
Madrigal Pharmaceuticals Inc Stock (MDGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):